Signs of progress against the superbugs, but not yet at the scale needed
The 2020 Antimicrobial Resistance Benchmark evaluates how 30 pharmaceutical companies are limiting drug-resistance.
Amsterdam, the Netherlands, 21 January 2020 – A core group of pharmaceutical companies are making progress in tackling the spread of antimicrobial resistance, new findings from the 2020 Antimicrobial Resistance Benchmark indicate. However, although a few companies are expanding their efforts, change is not happening at the scale needed to radically impact the threat from drug resistance.
Click link: Report summary